Ocupress en es it fr

Ocupress Brand names, Ocupress Analogs

Ocupress Brand Names Mixture

  • No information avaliable

Ocupress Chemical_Formula


Ocupress RX_link


Ocupress fda sheet

Ocupress msds (material safety sheet)

Ocupress Synthesis Reference

No information avaliable

Ocupress Molecular Weight

292.373 g/mol

Ocupress Melting Point

No information avaliable

Ocupress H2O Solubility

No information avaliable

Ocupress State


Ocupress LogP


Ocupress Dosage Forms

Ophthalmic Solution (1%)

Ocupress Indication

For the treatment of intraocular hypertension and chronic open-angle glaucoma

Ocupress Pharmacology

Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Ocupress Absorption

No information avaliable

Ocupress side effects and Toxicity

The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.

Ocupress Patient Information

No information avaliable

Ocupress Organisms Affected

Humans and other mammals